Please assess the completion status of the following clinical trial:

Trial Title: Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy if one is needed according to the American Gastroenterological Association (AGA) criteria, with no clinically significant findings~* Patient has no clinically significant findings on a physical examination and clinical laboratory tests~* Patient meets protocol criteria for CIC: reports \< 3 bowel movements (BMs) per week and reports one or more of the following during ≥ 25% of BMs: straining, lumpy or hard stools, sensation of incomplete evacuation during the 3 months before the diagnosis with the onset at least 6 months before the diagnosis~* Patient is compliant with daily interactive voice response system (IVRS) calls~* Patient reports an average of \< 3 complete spontaneous BMs (CSBMs) and ≤ 6 SBMs per week by the IVRS over the 14 calendar days before the Randomization Visit and the calendar day of Randomization.~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with irritable bowel syndrome (IBS)~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments~* Patient has Bristol Stool Form Scale score of 7 during Pretreatment period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 72 μg linaclotide (Type: EXPERIMENTAL): 72 μg oral linaclotide, once daily for 12 weeks
- 145 μg linaclotide (Type: EXPERIMENTAL): 145 μg oral linaclotide, once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).